Company
portal.bio
Boost any cargo into any cell, and unlock novel assays and next-gen cell therapies.
Also known as Portal, Portal Biotechnologies
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- biopharma and academic partners
- Legal name
- Portal Biotechnologies
Claim, correct or request removal
Record updated 28 September 2026
About
Portal's mission is to develop a universal cell engineering platform. We believe our technology has both transformative potential for research applications and could democratize cell therapies by broadening their biological potential and improving their accessibility.
Funding snapshot
- Total raised
- $20.7MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $9M2026-06-18
Funding rounds
- Round, 2026
- $9M2026-06-18, Company stated
- Round, 2026
- $9M2026-05-15, SEC form D sold, 12 investors
- Seed
- $7M2024-12-19, Company stated
- Round, 2024
- $11.7M2024-12-11, SEC form D sold, 43 investors
Products
- Other
- Controllable Surface Receptor Expression Kit
- Hardware
- Gateway
Loading relationship preview